Table 6 Multivariable Cox Proportional Hazards Model National Cancer Data Base 2010–2017 Patients ≥70 with cT1–3/cN0–3, Triple Negative or HER2 Positive invasive breast cancer treated with surgery first (±systemic therapy to follow) and chemotherapy first (±surgery to follow) Adjusted for age, clinical T stage, clinical N stage, hormone receptors status, and comorbidity (N = 2326)

From: Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer

Variable

Hazard ratio

95% confidence interval

p-Value

Age (per year increase)

1.06

1.05–1.07

≤.0001

Clinical T stage (cT)

 T1

Reference

 

≤.0001

 T2

1.55

1.35–1.78

 

 T3

2.25

1.81–2.79

 

Clinical N stage (cN)

 N0

Reference

 

≤.01

 N1

1.24

1.07–1.45

 

 N2/3

1.42

1.09–1.83

 

Year of Diagnosis

  

0.22

 2010–2012

Reference

  

 2013–2015

0.92

0.81–1.05

 

 2016–2017

0.81

0.66–0.99

 

Hormone Receptor

 Negative

Reference

 

0.01

 Positive

0.84

0.74–0.96

 

Charlson/Deyo Score

 2

Reference

 

<0.0001

 3

1.29

1.14–1.47

 

Treatment Start)

 Surgery (±adjuvant chemotherapy)

Reference

 

0.08

 Chemotherapy (±surgery to follow)

1.21

0.98–1.49

 
  1. *The Charlson/Deyo value is a weighted score derived from the sum of the scores for comorbid conditions. Comorbid conditions with a score of 1 include myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, or diabetes. Comorbid conditions with a score of 2 include a single diagnosis of diabetes with complications, hemiplegia/paraplegia, or renal disease. Comorbid conditions with a score of 3 include moderate /severe liver disease or AIDS. A cumulative score of ≥3 is classified as a Charslon/Deyo score of 3.
  2. **The American Joint Committee on Cancer Breast Cancer Staging Edition 7 was used for this analysis.
Back to article page